Compare PRVA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | TNGX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.7B |
| IPO Year | 2021 | 2020 |
| Metric | PRVA | TNGX |
|---|---|---|
| Price | $24.81 | $21.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $31.17 | $21.78 |
| AVG Volume (30 Days) | 690.6K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | 26.89 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $2,122,842,000.00 | $62,384,000.00 |
| Revenue This Year | $18.19 | N/A |
| Revenue Next Year | $10.72 | N/A |
| P/E Ratio | $137.50 | ★ N/A |
| Revenue Growth | 22.26 | ★ 48.29 |
| 52 Week Low | $18.78 | $1.04 |
| 52 Week High | $26.51 | $28.41 |
| Indicator | PRVA | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 68.00 | 45.80 |
| Support Level | $22.63 | $6.83 |
| Resistance Level | $25.23 | $22.01 |
| Average True Range (ATR) | 0.74 | 1.87 |
| MACD | 0.16 | -0.60 |
| Stochastic Oscillator | 98.18 | 17.19 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.